Compare DPZ & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DPZ | CORT |
|---|---|---|
| Founded | 1960 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.0B | 9.7B |
| IPO Year | 2004 | 2001 |
| Metric | DPZ | CORT |
|---|---|---|
| Price | $300.27 | $91.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 5 |
| Target Price | ★ $434.29 | $96.50 |
| AVG Volume (30 Days) | 938.6K | ★ 986.8K |
| Earning Date | 04-27-2026 | 04-30-2026 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | ★ 5.27 | N/A |
| EPS | ★ 4.13 | N/A |
| Revenue | ★ $4,939,994,000.00 | $761,407,000.00 |
| Revenue This Year | $7.98 | $26.08 |
| Revenue Next Year | $3.97 | $26.98 |
| P/E Ratio | $72.47 | ★ N/A |
| Revenue Growth | 4.96 | ★ 12.79 |
| 52 Week Low | $282.00 | $28.66 |
| 52 Week High | $496.00 | $95.11 |
| Indicator | DPZ | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 45.55 | 74.13 |
| Support Level | $298.86 | $76.41 |
| Resistance Level | $323.20 | N/A |
| Average True Range (ATR) | 9.99 | 3.67 |
| MACD | 1.18 | -0.17 |
| Stochastic Oscillator | 48.41 | 81.05 |
Domino's is the world's largest pizza chain, surpassing $20 billion in system sales with over 22,100 stores across more than 90 markets at the end of 2025. Around 33% of its units are in the US. The business is 99% franchised. Domino's operates through three segments: supply chain (60% of revenue), US stores (33%), and international franchises (7%). The firm generates the bulk of its revenue by supplying food to stores in the US and Canada through a vertically integrated network of 25 manufacturing and supply chain facilities, which primarily produce and distribute dough, and collecting brand royalties and marketing fees from franchisees. Domino's also generates revenue from sales at company-owned stores.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.